Advances in Acute Myeloid Leukemia Management: Focus on Secondary Disease and Older Patients
| Autor: | Daniel A. Pollyea |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Focus (computing) business.industry Secondary disease Myeloid leukemia 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology Older patients hemic and lymphatic diseases 030220 oncology & carcinogenesis medicine Intensive care medicine business neoplasms |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 18:1785-1787 |
| ISSN: | 1540-1413 1540-1405 |
| DOI: | 10.6004/jnccn.2020.5039 |
| Popis: | The “Age of Induction” led to breakthroughs in the treatment landscape for acute myeloid leukemia (AML), and was immediately followed by a long period during which few drugs were approved. That all changed a few years ago, when 2017 began the “Age of Abundance.” With many treatment options now available, new management strategies have emerged for patients with secondary AML, as well as for older patients with AML. Treatment can now be tailored to these special populations, and providers should be aware of the unique supportive care considerations associated with these newer AML therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|